Baricitinib (INCB28050, LY3009104) supplier|cas 1187594-09-7 |DC Chemicals|Supplier|Price|Buy  

Baricitinib (INCB28050, LY3009104) supplier|cas 1187594-09-7 |DC Chemicals|Supplier|Price|Buy

DC Chemicals Supply: Baricitinib (INCB28050, LY3009104) supplier,cas 1187594-09-7, Cat No. DC5064, In stock

Contact: website:www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642824；

Product name: Baricitinib (INCB28050, LY3009104), Synonym:　Baricitinib, INCB28050, LY3009104., Cat No. DC5064, Cas: 1187594-09-7, Chemical Name:N/A, Molecular Formula: C16H17N7O2S, MW: 371.4

Baricitinib (INCB28050, LY3009104),cas 1187594-09-7, Purity: >98%. Best Price and quality in the market,DC Chemicals,Primary Manufacturer, confirmed by HNMR and HPLC. Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3.

Baricitinib, also known as INCB028050 or LY3009104,  is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. Significant efficacy, as assessed by improvements in clinical, histologic and radiographic signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3. Diminution of inflammatory Th1 and Th17 associated cytokine mRNA levels was observed in the draining lymph nodes of treated rats. INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects. These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.